INDBInternet News Database 2.5 Updated just now · 297 sources Show or hide images Light or dark

Lower CagriSema Doses Beat Placebo; Early Response Matters

Save Like Comments Compare coverage

Summary

Results from the phase 3 REDFINE 9 trial show that a lower dose of CagriSema is superior to placebo, which could give clinicians more flexibility with treatment.

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    Lower CagriSema Doses Beat Placebo; Early Response Matters

    Results from the phase 3 REDFINE 9 trial show that a lower dose of CagriSema is superior to placebo, which could give clinicians more flexibility with treatment.

Comments

Comments need JavaScript.